

Dabrafenib & Trametinib

Reference Number: F4739
Date of Response: 15/08/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

A) Over the previous 6 months (Latest data includes February 2022 – April 2022), how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:

1) Metastatic Melanoma

6 patients were treated with a combination of Dabrafenib + Trametinib

2) Adjuvant Melanoma

***≤5 patients were treated with a combination of Dabrafenib + Trametinib**

3) BRAF mutated Lung Cancer

***≤5 patients were treated with a combination of Dabrafenib + Trametinib.**

*** In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.**